Forewarned is Forearmed: chronic spontaneous urticaria as a potential risk to effective SARS-COV-2 vaccine uptake and global public health.

Chronic spontaneous urticaria and angioedema (CSU/A) is a common condition with an estimated global point prevalence of 0.7% (95% C.I, 0.2-1.4)(1), higher in non-White populations. Symptoms present as an 'allergy mimic' but are underpinned by non-specific, non-IgE-mediated mast cell histamine release. The combination of common population prevalence and likelihood of vaccines precipitating symptoms in those with CSU/A presents an immediate risk to the SARS-COV-2 global vaccine program.